Sugiyama Yuichi | Graduate School of Pharmaceutical Sciences, University of Tokyo
スポンサーリンク
概要
関連著者
-
Kato Y
Graduate School Of Pharmaceutical Sciences University Of Tokyo
-
HORIKAWA Masato
Graduate School of Pharmaceutical Sciences, University of Tokyo
-
Horikawa Masato
Graduate School Of Pharmaceutical Sciences University Of Tokyo
-
Kato Yukio
Graduate School Of Pharmaceutical Sciences University Of Tokyo
-
Kato Y
Department Of Dental And Medical Biochemistry Hiroshima University Graduate School Of Biomedical Sci
-
Sugiyama Yuichi
Graduate School Of Pharmaceutical Sciences University Of Tokyo
-
Sugiyama Yuichi
Graduate School of Pharmaceutical Sciences, University of Tokyo
-
SUGIYAMA Yuichi
Graduate School of Pharmaceutical Sciences, The University of Tokyo
-
Tyson Charles
東京大学 薬学系研究
-
Tyson Charles
Toxicology Laboratory Sri International
-
KATO Yukio
Graduate School of Pharmaceutical Sciences, University of Tokyo
-
Kato Yukio
Graduate School Of Natural Science And Technology Kanazawa University
-
Sugiyama Yuichi
Graduate School Of Pharmaceutical Sciences The University Of Tokyo
-
Sugiyama Yuichi
Graduate School Of Pharmaceutical Sciences The Univ. Of Tokyo
-
Sugiyama Yuichi
Graduate School of Industrial Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan
-
KATO Yukio
Department of Dental and Medical Biochemistry, Hiroshima University Graduate School of Biomedical Sc
-
SUGIYAMA Yuichi
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
-
Kato Yukio
Department Of Applied Biological Science Tokyo University Of Science
-
HORIKAWA Masato
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo
-
Sugiyama Yuichi
Department Of Applied Biological Science Faculty Of Science And Technology Science University Of Tok
著作論文
- Potential Cholestatic Activity of Various Therapeutic Agents Assessed by Bile Canalicular Membrane Vesicles Isolated from Rats and Humans
- The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents : Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites
- 22D-11-2 Modifying the pharmacokinetics of the anticancer drug CPT-11, and its active metabolite SN-38, aimed at reducing the biliary excretion of SN-38 and its gastrointestinal toxicity.